Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8987142 | 0.94 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8987451 | 0.91 | LTB4R (0.83) | LTB4R | |
| SCHEMBL8987110 | 0.90 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8986968 | 0.90 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8987302 | 0.90 | LTB4R (0.87) | LTB4R | |
| SCHEMBL8987337 | 0.89 | LTB4R (1.00) | LTB4R | |
| SCHEMBL8987296 | 0.87 | LTB4R (0.80) | LTB4R | |
| SCHEMBL8987150 | 0.86 | LTB4R (0.79) | LTB4R | |
| SCHEMBL8987379 | 0.85 | LTB4R (0.83) | LTB4R | |
| SCHEMBL8986967 | 0.85 | LTB4R (1.00) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |